Cognitive ADHD Videogame Exploratory Study

Not Applicable

Completed

• Conditions: Attention Deficit Hyperactivity Disorder
• Interventions: Device: Neuro-typical controls and ADHD will receive EVO game play.

• Registration Number: NCT01943539
• Lead Sponsor: Akili Interactive Labs, Inc.

Brief Summary

A study in ADHD and neuro-typical children to assess EVO game play over 29 days.

Detailed Description

A study in children ages 8 to 12 to assess EVO cognitive game play. The study examines two populations, children diagnosed with ADHD (ADHD and not on medication) and neuro-typical children. The investigators plan to evaluate 80 subjects (N = 40 per group) in three site locations over a 29 day study period. The 29 day study period includes 2 in-clinic sessions and 27 days of out-patient game play. During the 27 days of out-patient game play, the subjects will be instructed to play EVO 5 days per week for typically 30 minutes per day

The investigators' hypothesis is that EVO will be playable and interesting to ADHD children and cognitive measures, as captured by EVO, will show a difference between ADHD children and age-matched neuro-typical children.

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2013-09-05
• Study First Submitted QC: 2013-09-12
• Study First Posted: 2013-09-17
• Primary Completion: 2015-05
• Study Completion: 2015-05
• Results First Submitted: 2017-06-26
• Status Verified: 2017-11
• Results First Submitted QC: 2017-11-14
• Last Update Submitted: 2017-11-14
• Results First Posted: 2017-12-13
• Last Update Posted: 2017-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

1. Age 8 to 12 at the time of parental informed consent.
2. Confirmed ADHD diagnosis at clinic per MINI-Kid (ADHD Cohort)
3. Baseline ADHD-RS-IV score >= 24 (ADHD Cohort), obtained at clinic
4. Baseline ADHD-RS-IV score <=13 (Neuro-typical Cohort), obtained at clinic
5. Consistently off ADHD drug for 1 week. Drugs include: Pre specified, oral psychostimulants (ADDERALL XR® [mixed salts of a single-entity amphetamine product], VYVANSE® [lisdexamfetamine dimesylate], CONCERTA® [methylphenidate HCl], FOCALIN XR® [dexmethylphenidate HCl], RITALIN LA® [methylphenidate HCl extended-release], METADATE CD® [methylphenidate HCl, USP], or FDA-approved generic equivalents )for 1 month (Other than ADHD drud
6. Consistently off Psychotropic drug for 1 month (Other than ADHD drug noted above)
7. Ability to follow written and verbal instructions (English)
8. Girls or Boys (Gender-matched - 30% girls minimum)
9. Functioning at an age-appropriate level intellectually.
10. Ability to comply with all the testing and requirements.

Exclusion Criteria

1. Current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator that may confound study data/assessments (per MINI-Kid).
2. Within the last 4 weeks, subject has entered or exited behavioral therapy. The subject should inform the Investigator if they intend to change their behavioral therapy during the 4 weeks of the study.
3. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation or self-injurious behavior (per C-SSRS).
4. History of failure to respond to an adequate trial of 2 treatments for ADHD (consisting of an appropriate dose and adequate duration of therapy and failure in efficacy in the opinion of the Investigator).
5. Motor condition that prevents game playing
6. Recent history (within the past 6 months) of suspected substance abuse or dependence.
7. History of seizures (exclusive of febrile seizures), a tic disorder, significant tics, or a current diagnosis of Tourette's Disorder.
8. Taken part in a clinical trial within 30 days prior to screening.
9. Diagnosis of color blindness
10. Regular use of psychoactive drugs that in the opinion of the Investigator may confound study data/assessments.
11. Any other medical condition that in the opinion of the Investigator may confound study data/assessments.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
EVO Game Play	Neuro-typical controls and ADHD will receive EVO game play.	Neuro-typical controls and ADHD will receive EVO game play.

Primary Outcome Measures

Name	Time	Method
Reaction Time in EVO Gameplay	28 days	EVO employs a perceptual discrimination attention/memory task as well as a continuous visuomotor "driving" task. Subjects were instructed to target a pre-specified stimulus, and ignore all other stimuli while navigating a road-like course. Reaction time was measured as the time between the initial presentation of the pre-specified target and when the subject tapped the tablet screen. Longer reaction times indicated a larger deficit in multitasking.
Number of Participants With Non-Treatment Related Adverse Events	Day 0 through Day 28 of the study	Another objective of this study is to evaluate the safety of EVO game play based on treatment-emergent adverse events (TEAEs) that may occur during this 28-day period of time.

Secondary Outcome Measures

Name	Time	Method
Time Spent Completing the Intervention	28 days	Time spent on completing the intervention is based on the prescribed therapy of 800 total minutes, or 13.3 hours, over the course of 28 days (7 sessions of EVO per day for 5 days per week for 4 weeks with each session lasting approximately 5.7 minutes long).

Trial Locations

Locations (2)

Florida Clinical Research Center, LLC; 🇺🇸 Bradenton, Florida, United States

Duke University; 🇺🇸 Durham, North Carolina, United States